Showing results (2131-2140 of 2,534) with videos related to
Sort By:
Pageof 254
Neurology|May 26, 2004
Bilateral generalized polymicrogyria (BGP): a distinct syndrome of cortical malformationB S Chang, X Piao, C Giannini, et al.Molecular Pharmaceutics|July 19, 2019
Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic MelanomaMengshi Li, Dijie Liu, Dongyoul Lee, et al.Therapeutic Advances in Musculoskeletal Disease|November 13, 2024
Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studiesLars Erik Kristensen, William Tillett, Peter Nash, et al.The European Journal of Neuroscience|December 1, 2022
Medio-dorsal thalamic dysconnectivity in chronic knee pain: A possible mechanism for negative affect and pain comorbiditySarina J Iwabuchi, Marianne M Drabek, William J Cottam, et al.Plos One|November 28, 2013
Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee jointJames J Burston, Devi Rani Sagar, Pin Shao, et al.Acta Crystallographica. Section D, Structural Biology|June 1, 2022
xia2.multiplex: a multi-crystal data-analysis pipelineRichard J Gildea, James Beilsten-Edmands, Danny Axford, et al.BMJ Open|August 8, 2020
Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 casesAndrew William Byrne, David McEvoy, Aine B Collins, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 16, 2005
Quantitative trait loci that determine BMD in C57BL/6J and 129S1/SvImJ inbred miceNaoki Ishimori, Renhua Li, Kenneth A Walsh, et al.Rheumatology and Therapy|November 14, 2025
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.Advances in Therapy|November 21, 2025
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A InhibitorsPhilip J Mease, Jessica A Walsh, Timothy P Fitzgerald, et al.Pageof 254